Catalyst Pharmaceuticals, based in Coral Gables, Florida, develops and commercializes novel medicines for rare diseases, including FIRDAPSE for Lambert-Eaton Myasthenic Syndrome and AGAMREE for Duchenne Muscular Dystrophy. The company, which went public in 2006, employs 167 people.
Gary Ingenito sold 180,096 shares of CPRX on 6 March at $21.67 per share, worth a total of $3.9M. They now own 68,873 CPRX shares, or a 72% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
